Skip to main content

Table 3 Patients with peak hs-TnT elevations

From: Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Protective strategyDexrazoxaneContinuous infusionCrossover
Patient Number81110
Peak hS-TnT > 5 ng/ml007
Peak hs-TnT > 10 ng/ml631